Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer

Oncogene

Volumn 32, Issue 12, 2013, Pages 1601-1608

  Ahlqvist, K ^a   Saamarthy, K ^a   Syed Khaja, A S ^a   Bjartell, A ^a   Massoumi, R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bcl 3; inhibitor of DNA binding (Id); interleukin 6; prostate cancer

Indexed keywords

DNA BINDING PROTEIN; DNA BINDING PROTEIN 1; DNA BINDING PROTEIN 2; ETOPOSIDE; HELIX LOOP HELIX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE; NUCLEIC ACID BINDING PROTEIN; PACLITAXEL; PROTEIN BCL 3; STAT1 PROTEIN; STAT3 PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INTERLEUKIN-6; MALE; NF-KAPPA B P52 SUBUNIT; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84884212418     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.175     Document Type: Article

References (45)

1. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-1721.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
5. Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa tumor microenvironment. Cancer Microenviron 2011; 4: 283-297.
6. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61: 8617-8623.
7. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740.
9. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542-549.
10. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch Jr G, Klocker H et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191: 239-244.
11. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998; 334(Part 2): 297-314.
12. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7: 2941-2948.
13. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001; 48: 47-53.
14. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000; 42: 1-7.
15. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 2007; 25: 477-489.
16. McKeithan TW, Rowley JD, Shows TB, Diaz MO. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1987; 84: 9257-9260.
17. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000; 19: 1123-1131.
18. Kuphal S, Shaw-Hallgren G, Eberl M, Karrer S, Aberger F, Bosserhoff AK et al. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma. Oncogene 2011; 30: 4523-4530.
19. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
20. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T et al. Downregulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009; 206: 221-232.
21. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003; 63: 8293-8301.
22. Choi HJ, Lee JM, Kim H, Nam HJ, Shin HJ, Kim D et al. Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun 2010; 400: 396-402.
23. Kashatus D, Cogswell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006; 20: 225-235.
24. Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllon V, Martinez AC. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 2000; 20: 3407-3416.
25. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K et al. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003; 102: 4123-4129.
26. Wessells J, Baer M, Young HA, Claudio E, Brown K, Siebenlist U et al. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 2004; 279: 49995-50003.
27. Keutgens A, Shostak K, Close P, Zhang X, Hennuy B, Aussems M et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol 2010; 30: 4006-4021.
28. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, Koczan D et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103: 242-251.
29. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
30. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010; 70: 3309-3319.
31. Cai C, Jiang FN, Liang YX, He HC, Han ZD, Dai QS et al. Classical and alternative nuclear factor-kB pathways: a comparison among normal prostate, benign prostate hyperplasia and prostate cancer. Pathol Oncol Res 2011; 17: 873-878.
32. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008; 68: 1725-1733.
33. Brocke-Heidrich K, Ge B, Cvijic H, Pfeifer G, Loffler D, Henze C et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006; 25: 7297-7304.
34. Forootan SS, Wong YC, Dodson A, Wang X, Lin K, Smith PH et al. Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer. Hum Pathol 2007; 38: 1321-1329.
35. Zielinski AJ, Fong S, Allison J, Kawahara M, Coppe JP, Feiler H et al. The helix-loophelix Id-1 inhibits PSA expression in prostate cancer cells. Int J Cancer 2010; 126: 2490-2496.
36. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004; 25: 881-887.
37. Hua H, Sarvetnick N. ID2 promotes the expansion and survival of growth-arrested pancreatic beta cells. Endocrine 2007; 32: 329-337.
38. Kim H, Chung H, Kim HJ, Lee JY, Oh MY, Kim Y et al. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res Treat 2008; 112: 287-296.
39. Monticelli LA, Yang Y, Knell J, D'Cruz LM, Cannarile MA, Engel I et al. Transcriptional regulator Id2 controls survival of hepatic NKT cells. Proc Natl Acad Sci USA 2009; 106: 19461-19466.
40. Zhang H, Lawson WE, Polosukhin VV, Pozzi A, Blackwell TS, Litingtung Y et al. Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice. Am J Pathol 2007; 171: 1113-1126.
41. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 2003; 22: 4498-4508.
42. Wong YC, Zhang XM, Ling MT, Wang XH. Inactivation of ID-1 gene induces sensitivity of prostate cancer cells to chemotherapeutic drugs. Adv Exp Med Biol 2008; 617: 565-572.
43. Zhang X, Ling MT, Wang Q, Lau CK, Leung SC, Lee TK et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 2007; 282: 33284-33294.
44. Zhang X, Ling MT, Wang X, Wong YC. Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 2006; 118: 2072-2081.
45. Zhang X, Ling MT, Wong YC, Wang X. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer druginduced apoptosis. Cancer Sci 2007; 98: 308-314.